Markets / Stocks

Aclaris Therapeutics Gets US Patent for Treating Seborrheic Keratosis

Aclaris Therapeutics (ACRS), a developer of therapies for aesthetic and medical dermatology and immunology, said early Wednesday that it was granted a US patent for covering methods of treating seborrheic keratosis, using a stabilized hydrogen peroxide composition.

The Orange Book-listed patent no. 9,980,983, issued by the US Patent and Trademark Office, will last until April 2035, subject to any term adjustment or extension, according to a statement.

The patent contains 25 claims directed to methods of treating seborrheic keratosis by administering a 40% w/w stabilized hydrogen peroxide composition. The company said its current marketed product, ESKATA, includes such stabilized hydrogen peroxide.